Vis enkel innførsel

dc.contributor.authorAaseth, Jan
dc.contributor.authorNurchi, Valeria M.
dc.date.accessioned2023-05-09T13:12:59Z
dc.date.available2023-05-09T13:12:59Z
dc.date.created2022-12-14T13:07:31Z
dc.date.issued2022
dc.identifier.citationBiomolecules. 2022, 12 (11):1713, .en_US
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/11250/3067321
dc.description.abstractThe chelating thiol dimercaptosuccinate (DMSA) and the traditional agent D-penicillamine (PSH) are effective in enhancing the urinary excretion of copper (Cu) and lead (Pb) in poisoned individuals. However, DMSA, PSH, EDTA (ethylenediamine tetraacetate), and deferoxamine (DFOA) are water-soluble agents with limited access to the central nervous system (CNS). Strategies for mobilization of metals such as manganese (Mn), iron (Fe), and Cu from brain deposits may require the combined use of two agents: one water-soluble agent to remove circulating metal into urine, in addition to an adjuvant shuttler to facilitate the brain-to-blood mobilization. The present review discusses the chemical basis of metal chelation and the ligand exchange of metal ions. To obtain increased excretion of Mn, Cu, and Fe, early experiences showed promising results for CaEDTA, PSH, and DFOA, respectively. Recent experiments have indicated that p-amino salicylate (PAS) plus CaEDTA may be a useful combination to remove Mn from binding sites in CNS, while the deferasirox-DFOA and the tetrathiomolybdate-DMSA combinations may be preferable to promote mobilization of Fe and Cu, respectively, from the CNS. Further research is requested to explore benefits of chelator combinations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687779/pdf/biomolecules-12-01713.pdf
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectDMSA;en_US
dc.subjectParkinson's disease;en_US
dc.subjectWilson's disease;en_US
dc.subjectchelating agents;en_US
dc.subjectcopper;en_US
dc.subjectdeferasirox;en_US
dc.subjectdeferiprone;en_US
dc.subjectiron;en_US
dc.subjectmanganese;en_US
dc.subjectneurodegenerative diseases;en_US
dc.subjectp-aminosalicylate;en_US
dc.titleChelation Combination - A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?en_US
dc.title.alternativeChelation Combination - A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.source.pagenumber13en_US
dc.source.volume12en_US
dc.source.journalBiomoleculesen_US
dc.source.issue11en_US
dc.identifier.doi10.3390/biom12111713
dc.identifier.cristin2093099
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal